NO20041339L - Spiro-hydantoin-forbindelser anvendelige som anti-inflammatoriske midler - Google Patents

Spiro-hydantoin-forbindelser anvendelige som anti-inflammatoriske midler

Info

Publication number
NO20041339L
NO20041339L NO20041339A NO20041339A NO20041339L NO 20041339 L NO20041339 L NO 20041339L NO 20041339 A NO20041339 A NO 20041339A NO 20041339 A NO20041339 A NO 20041339A NO 20041339 L NO20041339 L NO 20041339L
Authority
NO
Norway
Prior art keywords
inflammatory agents
compounds useful
spirohydantoin compounds
spirohydantoin
useful
Prior art date
Application number
NO20041339A
Other languages
English (en)
Norwegian (no)
Other versions
NO20041339D0 (no
Inventor
Eric Antoine Nicolai
Murali T G Dhar
Dominique Potin
Magaili Jeannine Bland Maillet
Michele Launay
Edwin J Iwanowicz
Original Assignee
Cerep Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cerep Sa filed Critical Cerep Sa
Publication of NO20041339D0 publication Critical patent/NO20041339D0/no
Publication of NO20041339L publication Critical patent/NO20041339L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/96—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/10—Spiro-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Pulmonology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Neurosurgery (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Dermatology (AREA)
  • Cardiology (AREA)
  • Endocrinology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Emergency Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Toxicology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Transplantation (AREA)
  • Vascular Medicine (AREA)
  • Obesity (AREA)
NO20041339A 2001-10-01 2004-03-31 Spiro-hydantoin-forbindelser anvendelige som anti-inflammatoriske midler NO20041339L (no)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US32636101P 2001-10-01 2001-10-01
US35411302P 2002-02-04 2002-02-04
US40025902P 2002-08-01 2002-08-01
PCT/US2002/031283 WO2003029245A1 (en) 2001-10-01 2002-09-30 Spiro-hydantoin compounds useful as anti-inflammatory agents

Publications (2)

Publication Number Publication Date
NO20041339D0 NO20041339D0 (no) 2004-03-31
NO20041339L true NO20041339L (no) 2004-05-24

Family

ID=27406458

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20041339A NO20041339L (no) 2001-10-01 2004-03-31 Spiro-hydantoin-forbindelser anvendelige som anti-inflammatoriske midler

Country Status (24)

Country Link
US (4) US6977267B2 (de)
EP (1) EP1432700B1 (de)
JP (1) JP4394442B2 (de)
KR (1) KR20040041649A (de)
CN (1) CN1596253A (de)
AR (1) AR036663A1 (de)
AT (1) ATE447565T1 (de)
BR (1) BR0213025A (de)
CA (1) CA2462112A1 (de)
DE (1) DE60234264D1 (de)
ES (1) ES2339107T3 (de)
GE (1) GEP20063767B (de)
HK (1) HK1063467A1 (de)
HR (1) HRP20040311A2 (de)
HU (1) HUP0402338A3 (de)
IL (1) IL160990A0 (de)
IS (1) IS7197A (de)
MX (1) MXPA04002993A (de)
NO (1) NO20041339L (de)
NZ (1) NZ531870A (de)
PE (1) PE20030845A1 (de)
PL (1) PL369337A1 (de)
RS (1) RS26604A (de)
WO (1) WO2003029245A1 (de)

Families Citing this family (70)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7687625B2 (en) * 2003-03-25 2010-03-30 Takeda Pharmaceutical Company Limited Dipeptidyl peptidase inhibitors
US7700583B2 (en) 2003-04-11 2010-04-20 High Point Pharmaceuticals, Llc 11β-hydroxysteroid dehydrogenase type 1 active compounds
EP1787982B1 (de) * 2003-04-11 2010-05-12 High Point Pharmaceuticals, LLC Verbindungen mit Aktivität an der 11Beta-Hydroxasteroiddehydrogenase
US7169926B1 (en) 2003-08-13 2007-01-30 Takeda Pharmaceutical Company Limited Dipeptidyl peptidase inhibitors
EP1506967B1 (de) * 2003-08-13 2007-11-21 Takeda Pharmaceutical Company Limited Dipeptidyl Peptidase Inhibitoren.
US7678909B1 (en) 2003-08-13 2010-03-16 Takeda Pharmaceutical Company Limited Dipeptidyl peptidase inhibitors
JP2007505121A (ja) * 2003-09-08 2007-03-08 武田薬品工業株式会社 ジペプチジルぺプチダーゼ阻害剤
EP1697342A2 (de) * 2003-09-08 2006-09-06 Takeda Pharmaceutical Company Limited Dipeptidyl peptidase inhibitoren
US7199125B2 (en) 2003-10-02 2007-04-03 Bristol-Myers Squibb Company Spiro-cyclic compounds useful as anti-inflammatory agents
CA2544678C (en) 2003-11-05 2013-12-31 Sunesis Pharmaceuticals, Inc. Modulators of cellular adhesion
AU2004305075A1 (en) 2003-12-19 2005-07-07 The Regents Of The University Of California Methods and materials for assessing prostate cancer therapies
AU2005232526B2 (en) 2004-02-24 2011-06-23 The Regents Of The University Of California Methods and materials for assessing prostate cancer therapies and compounds
US7732446B1 (en) 2004-03-11 2010-06-08 Takeda Pharmaceutical Company Limited Dipeptidyl peptidase inhibitors
CN102127057A (zh) 2004-03-15 2011-07-20 武田药品工业株式会社 二肽基肽酶抑制剂
EP1753730A1 (de) * 2004-06-04 2007-02-21 Takeda Pharmaceutical Company Limited Dipeptidylpeptidasehemmer
PL2433943T3 (pl) 2004-07-01 2014-04-30 Daiichi Sankyo Co Ltd Intermediaty dla pochodnych tienopirazolowych wykazujące efekt hamowania PDE 7
WO2006019965A2 (en) 2004-07-16 2006-02-23 Takeda San Diego, Inc. Dipeptidyl peptidase inhibitors
US7375237B2 (en) 2004-08-18 2008-05-20 Bristol-Myers Squibb Company Pyrrolizine compounds useful as anti-inflammatory agents
TW200616634A (en) * 2004-10-01 2006-06-01 Bristol Myers Squibb Co Crystalline forms and process for preparing spiro-hydantoin compounds
US8110581B2 (en) 2004-11-10 2012-02-07 Incyte Corporation Lactam compounds and their use as pharmaceuticals
EP1812005B1 (de) 2004-11-10 2015-09-16 Incyte Corporation Lactam-verbindungen und ihre verwendung als pharmazeutika
US7186727B2 (en) * 2004-12-14 2007-03-06 Bristol-Myers Squibb Company Pyridyl-substituted spiro-hydantoin compounds and use thereof
US20060142319A1 (en) * 2004-12-14 2006-06-29 Bang-Chi Chen Pyridyl-substituted spiro-hydantoin crystalline forms and process
WO2006068978A2 (en) * 2004-12-21 2006-06-29 Takeda Pharmaceutial Company Limited Dipeptidyl peptidase inhibitors
JP5273721B2 (ja) * 2005-03-21 2013-08-28 ビカス セラピューティクス，エルエルシー 悪液質を緩和するための組成物および方法
US20080033027A1 (en) * 2005-03-21 2008-02-07 Vicus Therapeutics Spe 1, Llc Drug combination pharmaceutical compositions and methods for using them
US20090117197A1 (en) * 2005-03-21 2009-05-07 Vicus Therapeutics Llc Compositions and methods for ameliorating cachexia
US7709517B2 (en) 2005-05-13 2010-05-04 The Regents Of The University Of California Diarylhydantoin compounds
JP2009507791A (ja) * 2005-08-29 2009-02-26 メルク エンド カムパニー インコーポレーテッド ナイアシン受容体アゴニスト、このような化合物を含有する組成物、および治療方法
EP1942898B2 (de) 2005-09-14 2014-05-14 Takeda Pharmaceutical Company Limited Dipeptidyl-peptidase-hemmer zur behandlung von diabetes
EA015735B1 (ru) * 2005-09-14 2011-10-31 Такеда Фармасьютикал Компани Лимитед Фармацевтические композиции на основе 2-[[6-[(3r)-3-амино-1-пиперидинил]-3,4-дигидро-3-метил-2,4-диоксо-1(2н)-пиримидинил]метил]бензонитрила
TW200745079A (en) * 2005-09-16 2007-12-16 Takeda Pharmaceuticals Co Polymorphs of benzoate salt of 2-[[6-[(3R)-3-amino-1-piperidinyl]-3,4-dihydro-3-methyl-2,4-dioxo-1(2H)-pyrimidinyl]methyl]-benzonitrile and methods of use therefor
KR101368988B1 (ko) * 2005-09-16 2014-02-28 다케다 야쿠힌 고교 가부시키가이샤 디펩티딜 펩티다제 억제제
TW200745080A (en) * 2005-09-16 2007-12-16 Takeda Pharmaceuticals Co Polymorphs of tartrate salt of 2-[2-(3-(R)-amino-piperidin-1-yl)-5-fluoro-6-oxo-6H-pyrimidin-1-ylmethyl]-benzonitrile and methods of use therefor
JP2009513576A (ja) * 2005-10-11 2009-04-02 インターミューン・インコーポレーテッド ウィルス複製のインヒビター
US8926990B2 (en) * 2009-10-13 2015-01-06 Rutgers, The State University Of New Jersey Treatment and diagnosis of inflammatory disorders and HIV
CN101032483B (zh) * 2006-03-09 2011-05-04 陈德桂 调节雄激素受体活性的乙内酰脲衍生物及其应用
EP2656842B1 (de) 2006-03-27 2016-08-10 The Regents of The University of California Androgenrezeptor-modulator zur behandlung von prostatakrebs und androgenrezeptor-assoziierte erkrankungen
WO2007112347A1 (en) 2006-03-28 2007-10-04 Takeda Pharmaceutical Company Limited Dipeptidyl peptidase inhibitors
EP1999108A1 (de) * 2006-03-28 2008-12-10 Takeda Pharmaceutical Company Limited Herstellung von (r)-3-aminopiperidin-dihydrochlorid
CA2648139A1 (en) 2006-03-29 2007-11-08 The Regents Of The University Of California Diaryl thiohydantoin compounds and their use in the treatment of hyperproliferative disorders
US7740064B2 (en) 2006-05-24 2010-06-22 Baker Hughes Incorporated System, method, and apparatus for downhole submersible pump having fiber optic communications
JP2010501567A (ja) 2006-08-24 2010-01-21 ノバルティス アクチエンゲゼルシャフト 代謝系、心血管系および他の障害の処置のためのステアロイル−ＣｏＡ不飽和化酵素（ＳＣＤ）阻害剤としての２−（ピラジン−２−イル）−チアゾールおよび２−（１Ｈ−ピラゾール−３−イル）チアゾール誘導体ならびに関連化合物
US8324383B2 (en) 2006-09-13 2012-12-04 Takeda Pharmaceutical Company Limited Methods of making polymorphs of benzoate salt of 2-[[6-[(3R)-3-amino-1-piperidinyl]-3,4-dihydro-3-methyl-2,4-dioxo-1(2H)-pyrimidinyl]methyl]-benzonitrile
PE20081150A1 (es) * 2006-09-13 2008-10-03 Takeda Pharmaceutical Inhibidores de dipetidilpeptidasa
MX2009003080A (es) 2006-09-22 2009-04-02 Novartis Ag Compuestos organicos heterociclicos.
TW200838536A (en) * 2006-11-29 2008-10-01 Takeda Pharmaceutical Polymorphs of succinate salt of 2-[6-(3-amino-piperidin-1-yl)-3-methyl-2,4-dioxo-3,4-dihydro-2H-pyrimidin-1-ylmethy]-4-fluor-benzonitrile and methods of use therefor
EP2121671A1 (de) 2006-12-20 2009-11-25 Novartis AG 2-substituierte fünfgliedrige heterocyclen als scd-hemmer
JPWO2008090944A1 (ja) 2007-01-25 2010-05-20 武田薬品工業株式会社 スピロ環化合物
WO2008096746A1 (ja) * 2007-02-06 2008-08-14 Takeda Pharmaceutical Company Limited スピロ化合物およびその用途
US8093236B2 (en) 2007-03-13 2012-01-10 Takeda Pharmaceuticals Company Limited Weekly administration of dipeptidyl peptidase inhibitors
WO2009011261A1 (ja) * 2007-07-19 2009-01-22 Tokuyama Corporation ヒダントイン環を有する化合物及びその製造方法
MX2010004281A (es) * 2007-10-19 2010-09-10 Sarcode Corp Composiciones y metodos para el tratamiento de la retinopatia diabetica.
UY31432A1 (es) 2007-10-26 2009-05-29 Compuestos de diarilhidantoina
US20090170770A1 (en) * 2007-11-06 2009-07-02 Ali Hafezi-Moghadam Methods and compositions for treating conditions associated with angiogenesis using a vascular adhesion protein-1 (vap 1) inhibitor
US8481750B2 (en) 2009-06-02 2013-07-09 Boehringer Ingelheim International Gmbh Derivatives of 6,7-dihydro-5H-imidazo[1,2-α]imidazole-3-carboxylic acid amides
WO2011029104A1 (en) 2009-09-04 2011-03-10 Vanderbilt University Mglur4 allosteric potentiators, compositions, and methods of treating neurological dysfunction
EA201792046A1 (ru) 2010-02-16 2018-05-31 Арагон Фармасьютикалс, Инк. Модуляторы рецептора андрогенов и их применение
KR20150046259A (ko) 2012-08-23 2015-04-29 앨리오스 바이오파마 인크. 파라믹소바이러스 바이러스성 감염의 치료용 화합물
NZ705815A (en) 2012-09-26 2018-08-31 Aragon Pharmaceuticals Inc Anti-androgens for the treatment of non-metastatic castrate-resistant prostate cancer
JOP20200097A1 (ar) 2013-01-15 2017-06-16 Aragon Pharmaceuticals Inc معدل مستقبل أندروجين واستخداماته
US20150065504A1 (en) * 2013-08-21 2015-03-05 Alios Biopharma, Inc. Antiviral compounds
CU24442B1 (es) * 2014-04-04 2019-09-04 X Rx Inc Derivados de n-(1-(espirocíclico)oxo) amida sustituidos como inhibidores de autotaxina
JP6633618B2 (ja) 2014-08-21 2020-01-22 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ 強力なｒｏｃｋ阻害剤としてのタイドバックのベンズアミド誘導体
MA41614A (fr) 2015-02-25 2018-01-02 Alios Biopharma Inc Composés antiviraux
TWI726969B (zh) 2016-01-11 2021-05-11 比利時商健生藥品公司 用作雄性激素受體拮抗劑之經取代之硫尿囊素衍生物
WO2017170830A1 (ja) * 2016-03-31 2017-10-05 武田薬品工業株式会社 複素環化合物
JOP20200076A1 (ar) 2017-10-16 2020-04-30 Aragon Pharmaceuticals Inc مضادات أندروجين لعلاج سرطان البروستاتا غير النقيلي المقاوم للاستئصال
EP4267118A1 (de) * 2020-12-24 2023-11-01 Axelyf ehf. Xanthophyllderivate
CN115536494B (zh) * 2022-10-31 2023-12-01 苏州诚和医药化学有限公司 1-(4-溴苯基)-1,4-丁二醇的合成方法

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1331757C (en) * 1988-02-29 1994-08-30 Janssen Pharmaceutica Naamloze Vennootschap 5-lipoxygenase inhibiting 4-(4-phenyl-1-piperazinyl)phenols
US5346913A (en) * 1992-05-26 1994-09-13 Rohm And Haas Company N-iodopropargyl hydantoin compounds, compositions, preparation, and use as antimicrobial agents
FR2694290B1 (fr) * 1992-07-08 1994-09-02 Roussel Uclaf Nouvelles phénylimidazolidines éventuellement substituées, leur procédé de préparation, leur application comme médicaments et les compositions pharmaceutiques les renfermant.
TW521073B (en) * 1994-01-05 2003-02-21 Hoechst Marion Roussel Inc New optionally substituted phenylimidazolidines, their preparation process, their use as anti-androgenic agent and the pharmaceutical compositions containing them
FR2741342B1 (fr) * 1995-11-22 1998-02-06 Roussel Uclaf Nouvelles phenylimidazolidines fluorees ou hydroxylees, procede, intermediaires de preparation, application comme medicaments, nouvelle utilisation et compositions pharmaceutiques
US6890915B2 (en) 2001-05-25 2005-05-10 Bristol-Myers Squibb Pharma Company Hydantoins and related heterocycles as inhibitors of matrix metalloproteinases and/or TNF-α converting enzyme (TACE)

Also Published As

Publication number Publication date
CN1596253A (zh) 2005-03-16
US6977267B2 (en) 2005-12-20
US20040009998A1 (en) 2004-01-15
PE20030845A1 (es) 2003-10-23
ES2339107T3 (es) 2010-05-17
NO20041339D0 (no) 2004-03-31
ATE447565T1 (de) 2009-11-15
KR20040041649A (ko) 2004-05-17
EP1432700A1 (de) 2004-06-30
GEP20063767B (en) 2006-03-10
HK1063467A1 (en) 2004-12-31
JP2005510476A (ja) 2005-04-21
HRP20040311A2 (en) 2005-02-28
DE60234264D1 (de) 2009-12-17
HUP0402338A2 (hu) 2005-02-28
EP1432700A4 (de) 2004-12-22
US20050004153A1 (en) 2005-01-06
BR0213025A (pt) 2004-10-05
JP4394442B2 (ja) 2010-01-06
PL369337A1 (en) 2005-04-18
US20040259897A1 (en) 2004-12-23
MXPA04002993A (es) 2004-07-15
NZ531870A (en) 2005-08-26
US20040248920A1 (en) 2004-12-09
IL160990A0 (en) 2004-08-31
HUP0402338A3 (en) 2008-10-28
CA2462112A1 (en) 2003-04-10
RS26604A (en) 2006-12-15
EP1432700B1 (de) 2009-11-04
IS7197A (is) 2004-03-24
WO2003029245A1 (en) 2003-04-10
US7078420B2 (en) 2006-07-18
AR036663A1 (es) 2004-09-22

Similar Documents

Publication Publication Date Title
NO20041339L (no) Spiro-hydantoin-forbindelser anvendelige som anti-inflammatoriske midler
NO20014412D0 (no) Forbindelser nyttige som anti-inflammatoriske midler
ATE309997T1 (de) Entzündungshemmende benzimidazolverbindungen
NO20033969D0 (no) Triazolpyridiner som anti-inflammatoriske midler
IS6971A (is) Ný efnasambönd
NO20042955L (no) Substituerte fenylaftalener som estrogene midler
DK1414803T3 (da) Pyrazolylcarboxanilider som fungicider
NO20035775L (no) 3-fluor-pyrrolidiner som anti-diabetesmidler
DK1429607T3 (da) Delta-1-pyrroliner som pesticider
DK1261588T3 (da) Imidazolforbindelser som alfa2-adrenoceptorantagonister
SE0104366D0 (sv) New compounds
SE0101659D0 (sv) New compounds
SE0102056D0 (sv) New Compounds
SE0103437D0 (sv) New compounds
SE0101660D0 (sv) New compounds
SE0103461D0 (sv) New compounds
SE0101958D0 (sv) New compounds
SE0102386D0 (sv) New compounds
SE0104342D0 (sv) New compounds
SE0100629D0 (sv) New compounds
SE0100272D0 (sv) New compounds
SE0104262D0 (sv) Chemical compound
SE0101239D0 (sv) Pharmaceutically useful compounds
SE0102807D0 (sv) Novel compounds
SE0100966D0 (sv) Novel compounds

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application